6-chloro-2-methyl-1H-indole-3-carboxylic acid methyl ester | 762288-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-chloro-2-methyl-1H-indole-3-carboxylic acid methyl ester
• 英文别名: methyl 6-chloro-2-methyl-indole-3-carboxylate；methyl 6-chloro-2-methyl-1H-indole-3-carboxylate
• CAS: 762288-09-5
• 化学式: C₁₁H₁₀ClNO₂
• 分子量: 223.659
• InChiKey: RPUAGJVFXJADEK-UHFFFAOYSA-N

物化性质

• 沸点：
  364.6±37.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-chloro-2-methyl-1H-indole-3-carboxylic acid methyl ester 在 水 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 生成 6-chloro-2-methyl-1H-indole-3-carboxylic acid
  参考文献：
  名称：

  N-（吡啶-2-基）苯并[b]五元杂环-3-甲酰胺结构化合物的制备与应用

  摘要：

  本发明涉及一类MAP3K5激酶的小分子抑制剂，具体涉及一种N‑（吡啶‑2‑基）苯并[b]五元杂环‑3‑甲酰胺结构化合物、其制备方法、药物组合物和在制备MAP3K5小分子抑制剂，或预防和/或治疗与MAP3K5相关疾病，尤其是肝脏疾病、肺部疾病、肿瘤、心血管疾病、肾脏疾病和代谢性疾病的药物中的用途。

  公开号：

  CN117756785A
• 作为产物：
  描述：

  乙酰乙酸甲酯 在 盐酸 、 titanium(III) chloride 、 sodium hydride 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-chloro-2-methyl-1H-indole-3-carboxylic acid methyl ester
  参考文献：
  名称：

  5-HT2C antagonists based on fused heterotricyclic templates: Design, synthesis and biological evaluation

  摘要：

  Design, synthesis and properties of a new tricyclic series of selective 5-HT2C receptor antagonists are reported. Conformational analysis of a 2-phenyl-dihydropyrrolone scaffold suggested that ring fusion, locking coplanarity between the rings of this moiety, might be tolerated by the 5-HT2C receptor. An interesting effect of this is the change of the nature of the carbon-carbon double bond of the lactam ring from vinylic to aromatic. The changes were found to result in a favourable profile at both, receptor and in vivo level. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.034

文献信息

• [EN] COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES AYANT UNE ACTIVITE AU NIVEAU DU RECEPTEUR 5HT2C ET LEURS UTILISATIONS
  申请人：GLAXO GROUP LTD

  公开号：WO2004081010A1

  公开（公告）日：2004-09-23

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein Q is phenyl or a 6-membered heteroaromatic group containing at least one nitrogen atom; A is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, or a group -(CHR3)- wherein R3 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; B is O, S or NR11, wherein R11 is hydrogen, C1-6alkyl optionally substituted by C1-6alkoxy, or is C1-6alkanoyl optionally substituted by C1-6alkoxy; R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1- 6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio, COR4 (wherein R4 is amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group), COOR5 or COR6 (wherein R5 and R6 are independently hydrogen or C1-6alkyl); p is 0, 1 or 2 or 3; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH2- or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Method of preparation and uses thereof in therapy, such as for example in treatment of depression and anxiety, are also disclosed.

  公开了具有式（I）的化合物及其药学上可接受的盐：其中Q是苯或含有至少一个氮原子的6元杂芳基团；A是-(CH2-CH2)-，-(CH=CH)-，-(CH2)3-，-C(CH3)2-，-(CH=CH-CH2)-，或一个-(CHR3)-基团，其中R3是氢，卤素，羟基，氰基，硝基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基或C1-6烷基硫基；B是O，S或NR11，其中R11是氢，C1-6烷基，可选择地被C1-6烷氧基取代，或是C1-6烷酰基，可选择地被C1-6烷氧基取代；R1是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷基硫基，羟基，氨基，单或双C1-6烷基氨基，N-连接的4到7成员杂环基团，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，芳基C1-6烷基，芳基C1-6烷氧基，芳基C1-6烷硫基，COR4（其中R4是氨基，单或双C1-6烷基氨基或N-连接的4到7成员杂环基团），COOR5或COR6（其中R5和R6独立地是氢或C1-6烷基）；p是0，1，2或3；R2是氢，卤素，羟基，氰基，硝基，C1-6烷基，C1-6烷酰基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷基硫基，氨基，单或双C1-6烷基氨基或N-连接的4到7成员杂环基团；X是氧，硫，-CH2-或NR8，其中R8是氢或C1-6烷基；Y是单键，-CH2-，-(CH2)2-或-CH=CH-；Z是一个可选择地取代的N-连接杂环基团或含有至少一个氮的C-连接的4到7成员杂环基团，或Z是-NR9R10，其中R9和R10独立地是氢或C1-6烷基。还公开了其制备方法及在治疗中的用途，例如在抑郁症和焦虑症的治疗中。
• Exploring the Oxidative Cyclization of Substituted <i>N</i> ‐Aryl Enamines: Pd‐Catalyzed Formation of Indoles from Anilines
  作者：Julia J. Neumann、Souvik Rakshit、Thomas Dröge、Sebastian Würtz、Frank Glorius

  DOI：10.1002/chem.201100631

  日期：2011.6.20

  The direct Pd‐catalyzed oxidative coupling of two CH‐bonds within N‐aryl‐enamines 1 allows the efficient formation of differently substituted indoles 2. In this cross‐dehydrogenative coupling, many different functional groups are tolerated and the starting material N‐aryl‐enamines 1 can be easily prepared in one step from commercially available anilines. In addition, the whole sequence can also be

  N-芳基-烯胺1中两个CH键的直接Pd催化氧化偶联可有效形成不同取代的吲哚2。在这种交叉脱氢偶联中，可以容忍许多不同的官能团，并且可以很容易地一步一步从市售苯胺制备起始原料N-芳基-烯胺1。此外，整个序列也可以单锅法运行。全文中报告了优化数据，机理见解，基材范围和应用。
• Preparation of indoles via iron catalyzed direct oxidative coupling
  作者：Zheng-Hui Guan、Ze-Yi Yan、Zhi-Hui Ren、Xue-Yuan Liu、Yong-Min Liang

  DOI：10.1039/b923971e

  日期：——

  Iron-catalyzed aryl C–H and vinyl C–H bonds activation to give valuable substituted indole products was reported. The reaction shows high functional group tolerance.

  报道了铁催化的芳基C–H和烯基C–H键活化，产生有价值的取代吲哚产物。该反应表现出良好的官能团耐受性。
• Compounds having activity at 5ht2c receptor and uses thereof
  申请人：Hamprecht Dieter

  公开号：US20060281786A1

  公开（公告）日：2006-12-14

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein Q is phenyl or a 6-membered heteroaromatic group containing at least one nitrogen atom; A is —(CH 2 —CH 2 )—, —(CH═CH)—, —(CH 2 ) 3 —, —C(CH 3 ) 2 —, —(CH═CH—CH 2 )—, or a group —(CHR 3 )— wherein R 3 is hydrogen, halogen, hydroxy, cyano, nitro, C 16 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy or C 1-6 alkylthio; B is O, S or NR 11 , wherein R 11 is hydrogen, C 1-6 alkyl optionally substituted by C 1-6 alkoxy, or is C 1-6 alkanoyl optionally substituted by C 1-6 alkoxy; R 1 is halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy, C 1 - 6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC 1 6 alkyl, haloC 1-6 alkoxy, aryl, arylC 1-6 alkyl, arylC 1-6 alkyloxy, arylC 1-6 alkylthio, COR 4 (wherein R 4 is amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group), COOR 5 or COR 6 (wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl); p is 0, 1 or 2 or 3; R 2 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 1-6 alkanoyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, —CH 2 — or NR 8 wherein R 8 is hydrogen or C 1-6 alkyl; Y is a single bond, —CH 2 —, —(CH 2 ) 2 13 or —CH═CH—; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is —NR 9 R 10 where R 9 and R 10 are independently hydrogen or C 1-6 alkyl. Method of preparation and uses thereof in therapy, such as for example in treatment of depression and anxiety, are also disclosed.

  公开了化合物式（I）及其药学上可接受的盐：其中Q是苯基或含有至少一个氮原子的6元杂环芳基基团；A是—（CH2—CH2）—，—（CH═CH）—，—（CH2）3—，—C（CH3）2—，—（CH═CH—CH2）—或—（CHR3）—基团，其中R3是氢，卤素，羟基，氰基，硝基，C16烷基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基或C1-6烷基硫基；B是O，S或NR11，其中R11是氢，C1-6烷基（可选地被C1-6烷氧基取代），或者是C1-6烷酰基（可选地被C1-6烷氧基取代）；R1是卤素，氰基，C1-6烷基，C3-7环烷基，C3-7环烷氧基，C1-6烷氧基，C1-6烷基硫基，羟基，氨基，单或双C1-6烷基氨基，N-连接的4至7元杂环基团，硝基，卤代C1-6烷基，卤代C1-6烷氧基，芳基，芳基C1-6烷基，芳基C1-6烷氧基，芳基C1-6烷基硫基，COR4（其中R4是氨基，单或双C1-6烷基氨基或N-连接的4至7元杂环基团），COOR5或COR6（其中R5和R6分别是氢或C1-6烷基）；p是0，1，2或3；R2是氢，卤素，羟基，氰基，硝基，C1-6烷基，C1-6烷酰基，C3-7环烷基，C3-7环烷氧基，卤代C1-6烷基，C1-6烷氧基，卤代C1-6烷氧基，C1-6烷基硫基，氨基，单或双C1-6烷基氨基或N-连接的4至7元杂环基团；X是氧，硫，—CH2—或NR8，其中R8是氢或C1-6烷基；Y是单键，—CH2—，—（CH2）2—或—CH═CH—；Z是可选取代的N-连接杂环基团或含有至少一个氮原子的C-连接4至7元杂环基团，或Z是—NR9R10，其中R9和R10分别是氢或C1-6烷基。公开了制备方法及其在治疗中的用途，例如治疗抑郁症和焦虑症。
• FXR AGONISTS
  申请人：Bell Michael Gregory

  公开号：US20090270460A1

  公开（公告）日：2009-10-29

  Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

  本发明公开了化学式为所定义变量的化合物及其制药组合物和使用方法，用于治疗血脂异常及相关疾病。